TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00350285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Personal feedback with counselor using motivational interviewing strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Marijuana education
Description: Information about health and behavioral effects of marijuana use.
Study: NCT03060681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block
Description: After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
Study: NCT02924961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon PS total knee system with mobile-bearing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PS total knee system with fixed-bearing
Study: NCT03942588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Study: NCT03841292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
Study: NCT03050125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar drop 2
Description: 240 mOsmol sterile saline drops used as a contact lens rewetting drop.
Study: NCT03841292

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Varenicline
Description: Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
Study: NCT00226655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCRF [XERECEPT (corticorelin acetate injection)]
Description: 2mg/day
Study: NCT03963882

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Second imaging evaluation
Description: Second imaging evaluation consists of pelvic magnetic resonance imaging
Study: NCT00691964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: SQ injection 50 mg BIW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SQ placebo injections for ABT-874 and etanercept
Study: NCT03329001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Capsule
Description: Niraparib capsule formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Capsule
Description: Niraparib capsule formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Capsule
Description: Niraparib capsule formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Capsule
Description: Niraparib capsule formulation
Study: NCT00622518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyland's earache drops
Description: 3-4 drops in affected ear 3 times a day as needed for up to 5 days
Study: NCT04167670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Over-encapsulated tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Over-encapsulated tablets administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Capsules administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Capsules administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Capsules administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Tablets administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Over-encapsulated capsules administered orally.
Study: NCT04952896

Intervention type: DIAGNOSTIC_TEST
Intervention: Synovitis diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Synovitis diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Synovitis diagnosis
Study: NCT04655872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TPN171H
Description: A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
Study: NCT02262871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen cannula
Description: HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
Study: NCT04022694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage health information
Description: Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage calorie information
Description: Calories for sugar-sweetened and non-sugar-sweetened beverages
Study: NCT00884988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymphomyosot
Description: 20 drops X3/day, until discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo remedy
Description: 20 drops X3/day, until discharge
Study: NCT00738088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gliclazide
Description: Gliclazide 80mg bd for 6 weeks
Study: NCT01685554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermic CPB
Description: maintenance of mild hypothermia during cardiopulmonary bypass

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: normothermic CPB
Description: maintenance of normal body temperature during cardiopulmonary bypass
Study: NCT02957448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS 986141
Description: Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
Study: NCT03050125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iso-osmolar drop
Description: 300 mOsmol sterile saline drops used as a contact lens rewetting drop.
Study: NCT03963882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The third cycles of neoadjuvant chemotherapy
Description: The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RH
Description: Radical hysterectomy
Study: NCT04224363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: staining from cervical esophagus to esophagogastric junction
Description: This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: staining from esophagogastric junction to cervical esophagus
Description: This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
Study: NCT01724281

Intervention type: OTHER
Intervention: No intervention, only follow up
Study: NCT02957448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
Study: NCT00031993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04542564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
Study: NCT01251679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand washing
Description: hand washing education and material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand washing and surgical mask
Description: hand washing education and material and paper surgical face masks
Study: NCT02728674

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom in the case is breathlessness.
Description: Symptom in the case is breathlessness.
Study: NCT00601978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa/levodopa
Study: NCT02800252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3g omega-3 plus 100mg aspirin daily for 60 days
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
Study: NCT00601978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa/Levodopa/Entacapone
Study: NCT03916068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trental Pill
Description: Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
Study: NCT02591615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475
Description: Dose frequency of Q3W, Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
Study: NCT03898570

Intervention type: BEHAVIORAL
Intervention: Patient reported outcomes
Description: Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys
Study: NCT03783195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar drink
Description: A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar drink
Description: A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
Study: NCT03884686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based education resource
Description: Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
Study: NCT02249741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treated with Ibandronic acid as per protocol
Description: treated with Ibandronic acid at a dose of 150 mg once a month for six months
Study: NCT04489654

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)
Description: deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
Study: NCT00907075

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NES With Energy Restriction
Description: The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NES Without Energy Restriction
Description: The NES will be administered based upon the individual's calculated daily energy requirement.
Study: NCT04116021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block
Description: Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
Study: NCT04790942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berberine hydrochloride
Description: the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle intervention group
Description: The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
Study: NCT02369783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and interview
Description: The aim is to detect social fragility.
Study: NCT04239417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises
Description: 1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Russian current stimulation
Description: The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises and the Russian current stimulation
Description: Combination between The Russian current and abdominal exercises
Study: NCT04627740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retroviral vector-transduced autologous T cells to express anti-ALPP CARs
Description: Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
Study: NCT00626873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Study: NCT01903876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bystander & Sexual Violence Prevention
Description: This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Promotion
Description: This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
Study: NCT03231514

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Supplement (Carb10)
Description: 2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Supplement (Carb10)
Description: 2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All groups will participate in a standardized exercise intervention.
Study: NCT05553743

Intervention type: DRUG
Intervention: Antibiotic
Description: Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
Study: NCT02728674

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom in the case is pain.
Description: Symptom in the case is pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Symptom in the case is pain.
Description: Symptom in the case is pain.
Study: NCT01996527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging
Description: 3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEST-MRI
Description: Undergo CEST-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DW-MRI
Description: Undergo DWI-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: Undergo DCE-MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSC-MRI
Description: Undergo DSC-MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of gadolinium-containing contrast agent
Description: Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
Study: NCT01887652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional ovarian stimulation
Description: a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individualized ovarian stimulation
Description: After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.